WAYLIVRA 285 mg, solution for injection in a pre-filled syringe syringe, 1.5 ml
Active ingredients: Volanesorsen, Volanesorsen sodium
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injectionsyringe, 1.5 mlsous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- WAYLIVRA 285 mg, solution injectable en seringue préremplie
- Pharmaceutical form
- solution injectable
- Route of administration
- sous-cutanée
- Presentation description
- 1 seringue préremplie en verre de 1,5 mL
- Marketing authorisation holder
- AKCEA THERAPEUTICS IRELAND (IRLANDE)
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 3 Sept 2019
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
65766872CIP73018196CIP133400930181966Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| VOLANÉSORSENsolution | 285 mg · une seringue préremplie de 1,5 mL | FT |
| VOLANÉSORSEN SODIQUEsolution | 300 mg · une seringue préremplie de 1,5 mL | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.